会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Gargle method to reduce the duration of common cold symptoms
    • 漱口法减少常见感冒症状的持续时间
    • US06641801B1
    • 2003-11-04
    • US09821653
    • 2001-03-28
    • Amy Christine Brown
    • Amy Christine Brown
    • A61K716
    • A61Q11/00A61K8/34A61K8/97A61K31/045A61K36/35A61K36/53A61K36/534A61K36/537A61K36/81A61K36/8962A61K2300/00
    • The common cold is caused by a virus. Antiviral compounds that kill viruses would then be most likely to serve as a remedy for the common cold. This invention seeks to offer a unique use of an antiviral agent, ethanol (with or without additional homeopathic and/or herb ingredients) through the unique topical application of a mouthwash to a sore throat that is often the first symptom of a common cold. The sore throat is caused by the virus setting up to enter the body after which a cascade of immune response symptoms will occur. Current cold remedies do nothing but treat these immune response symptoms. This invention is unique in that it destroys the virus directly, blocking the cold virus at its point of entry, and the remaining cold symptoms never appear. It does not matter how many cold viruses exist, because the antiviral nature of ethanol kills viruses upon contact. This is the first time that treatment of a sore-throat with antiviral agents (ethanol with or without additional homeopathic and/or herb ingredients) is being used to effectively block the common cold. Research testing this common cold remedy have shown it to be effective in 18 out of 20 case studies, and a double-blind, placebo controlled clinical trial is being conducted.
    • 感冒是由病毒引起的。 那么杀死病毒的抗病毒化合物最有可能成为感冒的补救方法。 本发明寻求通过将唯一的局部应用漱口剂施用于通常是常见感冒的第一症状的喉咙痛来提供抗病毒剂,乙醇(具有或不具有额外的顺势疗法和/或草药成分)的独特用途。 喉咙痛是由病毒进入身体引起的,之后会发生一系列免疫应答症状。 目前的冷治疗方法除了治疗这些免疫反应症状外,什么都不做。 本发明的独特之处在于它直接破坏病毒,在入口处阻止感冒病毒,并且其余的感冒症状不会出现。 存在多少感冒病毒并不重要,因为乙醇的抗病毒性质在接触时会杀死病毒。 这是第一次使用抗病毒药物(含或不含附加顺势疗法和/或草药成分的乙醇)治疗咽喉炎,有效阻止感冒。 研究测试这种常见的感冒治疗措施已经显示在20例病例研究中的18项中有效,并进行了双盲安慰剂对照临床试验。